Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4835096 | 0.92 | TAAR1 (0.48) | HDAC6CHEK2TAAR1DRD4KDR | |
| Trifluoroacetic Acid SCHEMBL4842803 | 0.92 | KMT2A (0.45) | HDAC6DRD4KMT2AMEN1 | |
| SCHEMBL4840783 | 0.92 | DRD4 (0.44) | HDAC6CHEK2DRD4KDRDRD2 | |
| Trifluoroacetic Acid SCHEMBL4840737 | 0.92 | HDAC6 (0.44) | HDAC6CHEK2 | |
| Trifluoroacetic Acid SCHEMBL4837280 | 0.91 | CDK4 (0.40) | HDAC6TAAR1DRD4DRD2DRD3 | |
| Trifluoroacetic Acid SCHEMBL4844131 | 0.91 | HDAC6 (0.39) | HDAC6CHEK2DRD4KMT2A | |
| Trifluoroacetic Acid SCHEMBL4844245 | 0.88 | MEN1 (0.47) | KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL4840541 | 0.87 | HTR5A (0.42) | HDAC6DRD4DRD2DRD3KMT2A | |
| Trifluoroacetic Acid SCHEMBL4843769 | 0.85 | KMT2A (0.43) | HDAC6KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL4845670 | 0.85 | FFAR1 (0.42) | CHEK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | HDAC6 981/4885CHEK2 309/4885TAAR1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.